Promising pCR Rates with Neoadjuvant Durvalumab Plus Platinum-based Chemotherapy Combined with ADC for Patients with Resectable NSCLC By Ogkologos - July 29, 2025 410 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NeoCOAST-2 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Factors Associated with COVID-19 Severity Among Patients with Cancer March 22, 2021 Shelter Cat Who Battled Breast Cancer Seeks Fellow Survivor to Give... October 30, 2019 New 5-Minute Injection Reduces Time Breast Cancer Patients Spend in Treatment April 8, 2021 Durvalumab Modestly Improves Survival in Advanced Biliary Tract Cancer February 10, 2022 Load more HOT NEWS 2023 ASCO Annual Meeting Research Round Up: New Research in Treating... The rise of the ‘long-waiter’ – why cancer waiting times are... Insights Into the Biology of Response and Resistance to MAPK Pathway... Stem cell research: meet the scientist growing ‘mini guts’ in her...
